A representative of the company developing the investigational CAR-T cell therapy noted that they hypothesize that the combination “has the potential to further enhance efficacy and provide patients with a chemotherapy-sparing, second-line treatment option.”
Investigators plan to analyze if treatment with an experimental, CAR-T cell therapy is safe and effective in a small group of patients with relapsed or refractory metastatic colorectal cancer.
A new study will analyze the effect of exercise on chemotherapy tolerability and outcomes in patients with colon cancer.
A phase 2 trial will analyze the novel drug ART4215 with Talzenna, a PARP inhibitor, for patients with BRCA-deficient breast cancer.
After findings from an early-phase trial showed that the novel drug was associated with anti-tumor activity, investigators decided to continue enrolling more patients with ER-positive, HER2-negative metastatic breast cancer.
Treatment with an investigational drug plus with Libtayo showed encouraging anti-tumor activity in patients with advanced metastatic castration-resistant prostate cancer, according to preliminary data from an early-phase trial.
Enrollment has begun on a phase 3 clinical trial assessing the safety and efficacy of an investigational cell therapy in patients with acute myeloid leukemia, acute lymphocytic leukemia and myelodysplastic syndromes.
A new treatment group within the PYNNACLE clinical trial is set to evaluate a novel drug plus Keytruda in patients with p53 Y220C-mutant locally advanced or metastatic solid tumors.
More than half of patients with metastatic, cisplatin-ineligible bladder cancer saw their cancer shrink when given Padcev and Keytruda in a clinical trial.
An ongoing clinical trial aims to determine if pre- and post-surgical chemotherapy can improve outcomes for patients with stage 2 and 3 gallbladder cancer.
ART27.13 may help increase appetite in patients undergoing cancer treatment.
Amazon and Fred Hutchinson Cancer Center recently launched an early-phase clinical trial to assess the safety and efficacy of a cancer vaccine in the treatment of patients with late-stage skin cancer or hormone receptor-positive, HER2-negative breast cancer.
The manufacturer of one of the cancer treatments announced that it is also participating in clinical trials assessing the safety and efficacy of their product in colorectal and endometrial cancer.
The first patient was dosed in a phase 2 trial studying the efficacy of sapanisertib in patients with NRF2-mutant relapsed/refractory lung cancer.
According to the manufacturer, this is the first-in-human clinical trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers.
The myeloma treatment group of the COVALENT-101 clinical trial recently started, analyzing the new drug BMF-219 in patients with relapsed or refractory disease.
The study the FDA allowed to continue is investigating the safety and efficacy of the novel cancer drug ACR-368 in patients with endometrial, urothelial and ovarian cancer.
A phase 2a trial is kicking off to study frontline GB1211 with the immunotherapy agent Tecentriq in patients with advanced or metastatic non-small cell lung cancer.
A clinical trial just launched to study Vaxinia — a novel cancer vaccine — in patients with previously treated advanced solid tumors.
Patients can still talk to their clinicians about enrolling in a sub-study of the FIRELIGHT-1 trial, analyzing tovorafenib plus pimasertib in progressive or refractory solid tumors with MAPK pathway aberrations.
The aim of the early-stage trial is to identify the safety of the experimental drug as either a single-agent therapy as well as in combination with Keytruda in adults with multiple solid tumors.
NX-5948 may be able to pass through the blood-brain barrier in patients with B-cell malignancies, potentially making it a promising option for patients with disease in their central nervous system.
The Strata PATH trial will use a novel testing strategy to determine if certain patients with solid tumors can benefit from already-approved therapies.
The hope, according to an expert, is that this trial will expand CAR-T cell therapy access to more patients with multiple myeloma.
Findings from an early-stage trial assessing Talzenna in combination with a novel drug, known as ZEN-3694, have led the manufacturer to initiate a later-stage study in patients with triple-negative breast cancer.
The primary objective of the early-stage trial is to determine the maximum tolerated dose of the novel drug in a group of patients with recurrent and/or refractory solid tumors.
Researchers are set to launch a new study to examine the feasibility of using an in-home virtual reality-guided mindfulness program to mitigate the effects of chronic cancer-related pain in patients and cancer survivors.
The first patient was dosed in a clinical trial evaluating the radiopharmaceutical agent, CycloSam, in patients with bone cancer or cancer that has metastasized to the bone.
The trial of CLR 131 (iopofosine) for relapsed/refractory Waldenstrom’s macroglobulinemia will continue, as the drug will be studied in an estimated 50 patients.
The first patient was dosed in the CLAUDIO-01 trial, analyzing SOTO102 in patients with certain types of gastric and pancreatic cancers.
